1月14日，强生（Johnson & Johnson）公司宣布斥资约146亿美元收购专注于开发中枢神经系统疾病疗法的Intra-Cellular Therapies公司。礼来（Eli Lilly and Company）宣布与Scorpion ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

回归本次交易的本质，和铂医药与Windward Bio完成的NewCo交易颇具里程碑意义。自此之后，和铂医药的盈利模式除了传统的两种外，又多了一项潜在的股权退出收益，这也意味着和铂医药的盈利能力在NewCo交易的推动下拥有了更高的增长潜力。

Investing.com -- GSK Plc的首席执行官Emma ...

Investing.com -- 英国制药公司GSK周一宣布，计划以高达11.5亿美元收购总部位于波士顿的生物制药公司IDRx。此举是GSK持续加强其在胃肠道癌症领域产品组合的一部分。 错过一次，就可能与财富翻倍的机会擦肩而过！用ProPicks，提前布局，6种AI选股模型助你今年的投资大放异彩！

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio ...